Registry‐based analysis of Icatibant and C1‐inhibitor use in treatment of laryngeal attacks of hereditary angioedema

Le résumé fourni par la source

The authors declare the following, real or perceived conflicts of interest: Roman Hakl has received a speaker/consultancy fees and travel grants from Pharming Group NV, CSL Behring, Shire and Takeda Pharmaceutical Co. Ltd and served as a Principal Investigator for clinical trials sponsored by BioCryst Pharmaceuticals, Pharvaris Netherlands BV, Pharming Group NV, CSL Behring and KalVista Pharmaceuticals. Pavel Kuklínek has received travel grants from Pharming Group NV, CSL Behring, Shire and Takeda and served as a sub-investigator for clinical trials sponsored by BioCryst Pharmaceuticals, Pharvaris Netherlands BV, Pharming Group NV, CSL Behring and KalVista Pharmaceuticals. Marta Sobotková reports being a consultant and speaker for Takeda, a consultant for Pharming and receiving symposium sponsorship from CSL Behring and Takeda. Pavlína Králičkova reports being a consultant and speaker for Takeda, and receiving symposium sponsorship from CSL Behring and Takeda. Irena Krčmová, Martina Vachová, Jana Hanzlíková, Martina Nováčková, Michal Svoboda, Ingrid Kováčová and Jiří Litzman have no conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.